0L49 Stock Chart & Stats
$3.68
$0.80(21.84%)
At close: 4:00 PM EDT
$3.68
$0.80(21.84%)
Day’s Range― - ―
52-Week Range$3.59 - $10.32
Previous CloseN/A
Volume11.29K
Average Volume (3M)314.00
Market Cap
$56.41M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 11, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume423
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside375.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet LeverageVery low leverage gives SCYNEXIS greater financial flexibility to fund development, support commercialization, and withstand operating volatility without the immediate burden of substantial debt service.
Approved Antifungal ProductAn approved product provides an established commercial and regulatory foundation in antifungal medicine, potentially supporting future label expansion and reducing the development risk relative to an entirely pre-commercial pipeline.
Partner-Led Commercialization ModelPartner-based commercialization can extend geographic reach while limiting the need for a large standalone sales infrastructure, preserving organizational efficiency and creating potential milestone and royalty revenue streams.
Bears Say
Persistent Unprofitable OperationsSustained operating and net losses weaken the durability of the business model, limit internally generated funding for clinical programs, and increase dependence on partnerships or future external capital.
Negative Cash GenerationOngoing cash consumption means current operations are not self-funding, potentially requiring financing, partnership proceeds, or spending reductions to maintain development and commercialization activities over the medium term.
Potential Equity DilutionExpanded issuance capacity and warrant-linked resale registration increase the potential future share supply, which may dilute existing ownership and provide management with a financing route that could weigh on per-share economics.
SCYNEXIS News
0L49 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $3.59 and its highest was $10.32 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $56.41M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.61.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -9.528%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in GB:0L49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (375.54% Upside)
$17.50 (375.54% Upside)
Blogger Sentiment
Bullish
GB:0L49 Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
0L49 Stock 12 Month Forecast
Average Price Target
$17.50
▲(375.54% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―